

Carbon Reduction Plan

Curium Pharma UK

Commitment To Achieving Carbon Net Zero

Curium Pharma UK is committed to achieving Net Zero by 2045 across its scopes 1, 2 and 3 emissions.

NHS supplier roadmap

Curium Pharma UK is implementing its Net Zero strategy in line with the NHS Net Zero Supplier Roadmap and PPN 006 requirements, targeting Net Zero emissions across the value chain by 2045.

Decarbonising operations

As a producer of SPECT and PET radiopharmaceuticals, Curium Pharma UK is progressively adapting its operations to support its Net Zero strategy.

Executive oversight

Curium Pharma UK Net Zero strategy is overseen by top management to ensure alignment, accountability and progress towards the 2045 target.

Carbon footprint methodology

Reporting boundaries

Organisational scope

Temporal Boundary

Carbon emissions reporting follows Curium Pharma's financial reporting period and is based on the calendar year. This report covers the period from 1 January to 31 December 2025.

Geographical Boundary

The reporting boundary covers Curium Pharma UK's current production network, including London Radiopharmacy (LRP) at the Institute of Nuclear Medicine, Hammersmith Radiopharmacy (HRP), and the Portsmouth head office. The network is currently being expanded with two new production sites in Oxford (Churchill Hospital) and Newcastle to support planned business growth.

Operational control

Carbon data Management

An annual carbon reporting process is conducted across all sites and offices. Data is based primarily on actual operational information (e.g. invoices) or, when unavailable, on estimates using production data and comparable sites. All data is supported by evidence and subject to internal validation to ensure consistency and comparability year on year.

Location vs Market-based emissions

Emission factors are currently primarily sourced from recognised databases, resulting mainly in a location-based approach. The company is progressively collecting more granular data, including supplier-specific emission factors, to improve accuracy and transition towards a market-based approach.

Carbon footprint methodology


GHG protocol & accounting limitations

GHG protocol framework

Curium Pharma UK follows the GHG Protocol methodology to calculate its carbon emissions. This framework classifies emissions into three scopes, covering direct and indirect emissions across the value chain (see graphic).

Carbon accounting boundaries

Curium Pharma UK carbon footprint currently covers all Scope 1 and Scope 2 emissions, as well as selected Scope 3 categories: category 4 (Upstream transportation and distribution), category 5 (Waste generated in operations), category 6 (Business travel), category 7 (Employee commuting) and category 9 (Downstream transportation and distribution). Transportation emissions are currently being refined, while remaining relevant Scope 3 categories are being quantified, with completion targeted by 2028.



Source: GHG Protocol

Finally, the following Scope 3 categories have been assessed as not relevant, as they do not occur within Curium UK's business model or are not material to operations:

- 8 – Upstream leased assets
- 13 – Downstream leased assets
- 14 – Franchises
- 15 – Investments

Baseline Year

2024 Carbon footprint

The baseline year is the reference year used to establish the company's carbon footprint before the implementation of emissions reduction initiatives.

It provides the reference point against which future carbon emissions (or other greenhouse gases) and decarbonisation progress are measured.

Carbon footprint - Baseline

Curium UK – 2024 (1 January 2024 to 31 December 2024)

EMISSIONS	in tCO2e
Scope 1	
Natural gas	15.9
Refrigerant gas	0.1
Diesel (back up generators)	0.0
Scope 2	
Electricity (location-based)	25.2
Heat	2.3
Scope 3	
4. Upstream transportation and distribution	18.6
5. Waste generated from operations	73.7
6. Business travel	25.4
7. Employee commuting	60.7
9. Downstream transportation and distribution	261.3
Total emissions	483.1

5.9 tCO2e/FTE

Carbon Intensity
per employee


As part of our commitment to continuous improvement, we continue to enhance the methodology used to calculate carbon emissions across all categories. When these improvements impact the baseline, it is updated to maintain consistency and enable accurate comparison with current-year emissions.

Reporting Year

2025 Carbon footprint

Between the baseline year and the reporting year, carbon emissions increased by 15%.

As Curium Pharma continues to grow, **absolute emissions are monitored alongside carbon intensity** to provide an additional perspective on environmental performance over time



Carbon footprint – Reporting period

Curium UK – 2025 (1 January 2025 to 31 December 2025)

EMISSIONS	in tCO ₂ e	Evolution (compared to baseline)
Scope 1		
Natural gas	22.8	+43.2%
Refrigerant gas	0.0	-100.0%
Diesel (back up generators)	0.0	-
Scope 2		
Electricity (location-based)	32.0	+27.0%
Heat	2.2	-2.2%
Scope 3		
4. Upstream transportation and distribution	20.6	+10.8%
5. Waste generated from operations	75.2	+2.1%
6. Business travel	22.1	-13.0%
7. Employee commuting	91.5	+50.7%
9. Downstream transportation and distribution	289.6	+10.8%
Total emissions	556.0	+15.1%

6.2 tCO₂e/FTE

Carbon Intensity per employee

The evolution of emissions between the baseline year and the reporting year varies across the emission categories, reflecting changes in business activities.

These changes are primarily driven by higher production volumes, as well as activities related to the preparation of the new Oxford site. Despite these developments, carbon intensity increased only slightly, from 5.9 to 6.2 tCO₂e/FTE.

The objective is to reduce carbon intensity through the implementation of the decarbonisation roadmap.

Carbon reduction actions

Implemented initiatives

As part of Curium Pharma UK's Net Zero strategy, initial measures have been implemented across operations to reduce environmental impacts and support the transition towards Net Zero.



Energy efficiency & Renewable electricity

Energy efficiency measures have been progressively implemented across Curium Pharma UK's sites to reduce Scope 2 emissions and energy consumption.

These include on-site renewable electricity generation through solar panels, as well as LED lighting, motion sensors and timers, with the Oxford site expected to save 1.5 MWh/year.



Waste & Circularity

Several waste optimisation initiatives contribute to reducing Scope 3 emissions associated with waste generation. Production processes have been continuously improved while maintaining product quality, resulting in a 0.2% decrease in waste generation between 2024 and 2025.

Lead shielding containers are also recovered through reverse logistics, reused whenever possible, and recycled at end-of-life.



Resource efficiency

Resource efficiency initiatives contribute to reducing Scope 3 emissions by limiting the consumption of critical raw materials. 0-18 recycling (enriched water used to manufacture PET products) is in its final implementation phase in the UK, following Group-level deployment.

Preventive maintenance and repair-first practices also support longer equipment lifetime.



Transport & Mobility

Business travel emissions are managed through a virtual-first approach, with air travel monitored.

Curium UK also promotes sustainable commuting through its Cycle to Work scheme, with 11% of employees enrolled since 2022.

Carbon reduction projects

Planned initiatives

Curium Pharma UK has planned a set of initiatives as part of its Net Zero strategy to further reduce its carbon footprint over the coming years. Additional measures will continue to be identified over time to support the transition towards Net Zero by 2045.



Energy efficiency & Renewable electricity

Further reductions in Scope 2 emissions will be supported by increased renewable electricity sourcing and energy efficiency measures. The Oxford site is planned to transition to a 100% renewable electricity contract by 2027, delivering an estimated market-based saving of ~37.5 tCO₂e/year.

New fan wall systems will also reduce HVAC consumption by an estimated 20.85 MWh/year.



Waste & Circularity

Waste reduction initiatives will continue to limit Scope 3 emissions associated with waste generation while supporting expected business growth. The deployment of an eQMS in 2027 will reduce paper consumption by approximately 312 kg/year, supporting a 50% reduction target by 2030.

Waste intensity will continue to be monitored as a complementary indicator.



Resource efficiency

Resource efficiency initiatives will further reduce Scope 3 emissions by limiting critical material consumption. O-18 recycling will be fully deployed in the UK by end of 2026, supporting a 100% recycled O-18 target by 2027.

Curium Pharma UK is also investigating lead-to-tungsten shielding, which could reduce lead use and container weight, lowering transport-related emissions.



Transport & Mobility

Efforts to reduce transport-related emissions will continue through more sustainable travel and logistics.

Planned measures include a ban on air travel where a direct rail alternative is available from 2027, a 10% reduction in business travel emissions by 2030, and Net Zero requirements in future logistics carrier tenders.

Declaration and Sign Off

This Carbon Reduction Plan has been completed in accordance with PPN 006 and associated guidance and reporting standard for Carbon Reduction Plans.

Emissions have been reported and recorded in accordance with the published reporting standard for Carbon Reduction Plans and the GHG Reporting Protocol corporate standard¹ and uses the appropriate Government emission conversion factors for greenhouse gas company reporting².

1. www.ghgprotocol.org/corporate-standard

2. www.gov.uk/government/collections/government-conversion-factors-for-company-reporting

3. www.ghgprotocol.org/corporate-value-chain-scope-3-standard

Scope 1 and Scope 2 emissions have been reported in accordance with SECR requirements, and the required subset of Scope 3 emissions have been reported in accordance with the published reporting standard for Carbon Reduction Plans and the Corporate Value Chain (Scope 3) Standard³.

This Carbon Reduction Plan has been reviewed and signed off by the board of directors (or equivalent management body).

Signed on behalf of the Supplier:

Date: July 2026

Ruairi O'Donnell

Ruairi O'Donnell, General manager